Sanofi

Symbol: SNY

NASDAQ

47.29

USD

Market price today

  • 16.4750

    P/E Ratio

  • 0.7523

    PEG Ratio

  • 109.53B

    MRK Cap

  • 0.04%

    DIV Yield

Sanofi (SNY) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.67%

Operating Profit Margin

0.21%

Net Profit Margin

0.12%

Return on Assets

0.00%

Return on Equity

0.10%

Return on Capital Employed

0.00%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO:Mr. Paul Hudson
Full-time employees:86088
City:Paris
Address:54, Rue La BoEtie
IPO:2002-07-01
CIK:0001121404

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

General Outlook

When we look at how much money they make before expenses, they keep 0.673% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.212%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.123%. This tells us they're good at keeping money after all costs.

Return on Investments

Sanofi's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.096%.

Stock Prices

Sanofi's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $50.37, while its low point bottomed out at $48.85. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Sanofi's stock market.

Profitability Ratios

SNY profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 15.82% underscores its earnings before tax deductions. The effective tax rate stands at 20.59%, revealing its tax efficiency. The net income per EBT, 77.79%, and the EBT per EBIT, 74.70%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 21.18%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin15.82%
Effective Tax Rate20.59%
Net Income per EBT77.79%
EBT per EBIT74.70%
EBIT per Revenue21.18%

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 8.21, and free cash flow per share, 5.61, depict cash generation on a per-share basis. The cash per share value, 6.97, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.18, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share8.21
Free Cash Flow per Share5.61
Cash per Share6.97
Operating Cash Flow Sales Ratio0.18
Free Cash Flow to Operating Cash Flow Ratio0.68
Capital Expenditure Coverage Ratio3.15
Dividend Paid and Capex Coverage Ratio3.15
Dividend Payout Ratio0.04

Debt and Leverage Ratios

An interest coverage of 6.54 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Interest Coverage6.54

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 34.41, provides a glimpse into top-line earnings distributed across each share. Net income per share, 4.31, reflects the portion of profit attributed to each share. The book value per share, 59.15, represents the net asset value distributed per share, while the tangible book value per share, -38.85, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share34.41
Net Income Per Share4.31
Book Value Per Share59.15
Tangible Book Value Per Share-38.85
Shareholders Equity Per Share59.15
Interest Debt Per Share14.19
Capex Per Share-2.60

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -5.11%, indicates top-line expansion, while the gross profit growth, -16.40%, reveals profitability trends. EBIT growth, -45.32%, and operating income growth, -45.32%, offer insights into operational profitability progression. The net income growth, -35.49%, showcases bottom-line expansion, and the EPS growth, -35.58%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-5.11%
Gross Profit Growth-16.40%
EBIT Growth-45.32%
Operating Income Growth-45.32%
Net Income Growth-35.49%
EPS Growth-35.58%
EPS Diluted Growth-35.44%
Weighted Average Shares Growth-0.02%
Weighted Average Shares Diluted Growth-0.04%
Dividends per Share Growth6.88%
Operating Cash Flow Growth-2.55%
Free Cash Flow Growth-15.86%
10-Year Revenue Growth per Share45.49%
5-Year Revenue Growth per Share20.28%
3-Year Revenue Growth per Share15.43%
10-Year Operating CF Growth per Share55.93%
5-Year Operating CF Growth per Share84.25%
3-Year Operating CF Growth per Share37.92%
10-Year Net Income Growth per Share53.57%
5-Year Net Income Growth per Share24.95%
3-Year Net Income Growth per Share-56.01%
10-Year Shareholders Equity Growth per Share37.58%
5-Year Shareholders Equity Growth per Share25.29%
3-Year Shareholders Equity Growth per Share17.70%
10-Year Dividend per Share Growth per Share29.41%
5-Year Dividend per Share Growth per Share17.62%
3-Year Dividend per Share Growth per Share13.30%
Receivables Growth2851.87%
Inventory Growth-53.79%
Asset Growth1.51%
Book Value per Share Growth1.24%
Debt Growth-13.15%
R&D Expense Growth0.28%
SGA Expenses Growth0.50%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 122,064,592,000, captures the company's total value, considering both debt and equity. Income quality, 1.90, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 58.18%, indicates the value of non-physical assets, and capex to operating cash flow, -31.71%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value122,064,592,000
Income Quality1.90
Research and Development to Revenue15.61%
Intangibles to Total Assets58.18%
Capex to Operating Cash Flow-31.71%
Capex to Revenue-7.55%
Capex to Depreciation-86.15%
Stock-Based Compensation to Revenue0.66%
Graham Number75.77
Return on Tangible Assets10.21%
Graham Net Net-23.98
Working Capital6,461,000,000
Tangible Asset Value780,000,000
Net Current Asset Value-21,456,000,000
Average Receivables5,707,000,000
Average Payables13,081,000,000
Average Inventory15,291,000,000
Days Sales Outstanding94
Days Payables Outstanding161
Days of Inventory On Hand213
ROIC7.86%
ROE0.07%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.57, and the price to book ratio, 1.57, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.03, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 16.66, and price to operating cash flows, 11.34, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.57
Price to Book Ratio1.57
Price to Sales Ratio2.03
Price Cash Flow Ratio11.34
Price Earnings to Growth Ratio0.75
Enterprise Value Multiple6.83
Price Fair Value1.57
Price to Operating Cash Flow Ratio11.34
Price to Free Cash Flows Ratio16.66
Price to Tangible Book Ratio1.52
Enterprise Value to Sales2.83
Enterprise Value Over EBITDA9.42
EV to Operating Cash Flow11.90
Earnings Yield4.81%
Free Cash Flow Yield6.23%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Sanofi (SNY) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 16.475 in 2024.

What is the ticker symbol of Sanofi stock?

The ticker symbol of Sanofi stock is SNY.

What is company IPO date?

IPO date of Sanofi is 2002-07-01.

What is company current share price?

Current share price is 47.290 USD.

What is stock market cap today?

The market cap of stock today is 109531463705.000.

What is PEG ratio in 2024?

The current 0.752 is 0.752 in 2024.

What is the number of employees in 2024?

In 2024 the company has 86088.